PT3134084T - Método de tratamento de adenocarcinoma do pulmão - Google Patents

Método de tratamento de adenocarcinoma do pulmão

Info

Publication number
PT3134084T
PT3134084T PT157211004T PT15721100T PT3134084T PT 3134084 T PT3134084 T PT 3134084T PT 157211004 T PT157211004 T PT 157211004T PT 15721100 T PT15721100 T PT 15721100T PT 3134084 T PT3134084 T PT 3134084T
Authority
PT
Portugal
Prior art keywords
lung adenocarcinoma
treating lung
treating
adenocarcinoma
lung
Prior art date
Application number
PT157211004T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3134084(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PT3134084T publication Critical patent/PT3134084T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT157211004T 2014-04-25 2015-04-27 Método de tratamento de adenocarcinoma do pulmão PT3134084T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461984599P 2014-04-25 2014-04-25

Publications (1)

Publication Number Publication Date
PT3134084T true PT3134084T (pt) 2021-05-11

Family

ID=53055132

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157211004T PT3134084T (pt) 2014-04-25 2015-04-27 Método de tratamento de adenocarcinoma do pulmão

Country Status (21)

Country Link
US (1) US20170042880A1 (cg-RX-API-DMAC7.html)
EP (2) EP3134084B1 (cg-RX-API-DMAC7.html)
JP (2) JP6696908B2 (cg-RX-API-DMAC7.html)
KR (1) KR102474701B1 (cg-RX-API-DMAC7.html)
CN (1) CN106488768A (cg-RX-API-DMAC7.html)
AR (1) AR100191A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015249232B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016024672A2 (cg-RX-API-DMAC7.html)
CA (1) CA2946416C (cg-RX-API-DMAC7.html)
DK (1) DK3134084T3 (cg-RX-API-DMAC7.html)
EA (1) EA035223B1 (cg-RX-API-DMAC7.html)
ES (1) ES2874875T3 (cg-RX-API-DMAC7.html)
HU (1) HUE054557T2 (cg-RX-API-DMAC7.html)
IL (1) IL248408B (cg-RX-API-DMAC7.html)
MX (1) MX375716B (cg-RX-API-DMAC7.html)
PL (1) PL3134084T3 (cg-RX-API-DMAC7.html)
PT (1) PT3134084T (cg-RX-API-DMAC7.html)
SG (1) SG11201608657QA (cg-RX-API-DMAC7.html)
TW (1) TWI724988B (cg-RX-API-DMAC7.html)
UA (1) UA121655C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015164869A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107353246A (zh) * 2016-12-27 2017-11-17 辅仁药业集团熙德隆肿瘤药品有限公司 一种制备抗肿瘤药物卡博替尼的方法
CA3059119C (en) * 2017-05-31 2024-01-23 F. Hoffman-La Roche Ag Multiplex pcr detection of alk, ret, and ros fusions
MX2019014298A (es) 2017-06-09 2020-02-03 Exelixis Inc Formas de dosificacion liquida para tratar el cancer.
CN107541550A (zh) * 2017-08-21 2018-01-05 上海派森诺生物科技股份有限公司 人ros1融合基因检测方法
JP7279026B2 (ja) * 2017-09-20 2023-05-22 メルサナ セラピューティクス インコーポレイテッド Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP3743417A1 (en) 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
DE102020005002A1 (de) * 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Mittel zur Therapie von Tumorerkrankungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP2392565B1 (en) * 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
US9096855B2 (en) 2007-10-18 2015-08-04 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
PT2387563E (pt) * 2009-01-16 2013-03-25 Exelixis Inc Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
EP2881402B1 (en) 2009-02-12 2017-05-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
TWI585088B (zh) * 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
WO2014039971A1 (en) * 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Also Published As

Publication number Publication date
EA035223B1 (ru) 2020-05-18
NZ725576A (en) 2021-03-26
AR100191A1 (es) 2016-09-14
HUE054557T2 (hu) 2021-09-28
IL248408A0 (en) 2016-11-30
WO2015164869A1 (en) 2015-10-29
EP3134084A1 (en) 2017-03-01
CA2946416A1 (en) 2015-10-29
JP6696908B2 (ja) 2020-05-20
KR20160147934A (ko) 2016-12-23
US20170042880A1 (en) 2017-02-16
CA2946416C (en) 2022-07-19
CN106488768A (zh) 2017-03-08
TWI724988B (zh) 2021-04-21
AU2015249232B2 (en) 2020-06-25
DK3134084T3 (da) 2021-05-03
PL3134084T3 (pl) 2021-09-27
AU2015249232A1 (en) 2016-11-10
EA201692150A1 (ru) 2017-02-28
SG11201608657QA (en) 2016-11-29
UA121655C2 (uk) 2020-07-10
MX2016013600A (es) 2017-04-27
TW201622723A (zh) 2016-07-01
IL248408B (en) 2022-06-01
BR112016024672A2 (pt) 2021-02-02
ES2874875T3 (es) 2021-11-05
JP2017513908A (ja) 2017-06-01
EP3906921A1 (en) 2021-11-10
MX375716B (es) 2025-03-06
JP2019189646A (ja) 2019-10-31
EP3134084B1 (en) 2021-03-17
KR102474701B1 (ko) 2022-12-05

Similar Documents

Publication Publication Date Title
IL304252A (en) Cancer treatment methods
IL276545B (en) A method for treating cancer
IL259783A (en) Methods of treatment of malignant diseases
IL248408A0 (en) A method for treating adenocarcinoma of the lungs
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
GB201701673D0 (en) Methods of well treatment
SG10201801562PA (en) Combination method for treatment of cancer
ZA201706059B (en) Method of treatment with tradipitant
NO20161459A1 (en) Method for treatment of underground reservoirs
GB201410116D0 (en) Method of treatment
IL255079A0 (en) Methods of treating lung cancer
IL253028A0 (en) treatment method
SG10201912688YA (en) A method of treatment
GB2558789B (en) Method of authentication
GB201416832D0 (en) Methods of treatment
GB201904142D0 (en) Improved method of FT-IMS
GB201521886D0 (en) A method of treating a well
GB201602802D0 (en) Method of treatment
GB201510197D0 (en) Method of treating ovarian cancer
GB201512139D0 (en) Methods of treatment
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment